Geoffrey and Matthew examine how efforts to improve patient access have contributed to an increasingly fragmented prescription journey. They suggest that a more integrated approach can reduce complexity, improve visibility and control for manufacturers, and create a simpler path to therapy for patients.
To learn more about the BlinkRx Prescription Journey Management Platform, visit BlinkRx.
Read on for Geoffrey and Matthew's insights.
BlinkRx Insights: Beyond the Hub - Rethinking the Prescription Journey
By Geoffrey Chaiken and Matthew Chaiken, Co-founders, BlinkRx
But how did we get here?
The sadly ironic answer: a string of well-meaning innovations in patient access over the past decades compounded the very problems they intended to solve.
Understanding how they undermined access clarifies what’s needed to solve the pressing national crisis.
Stage 1: Retail Pharmacies Under Pressure
Historically, retail pharmacies carried the burden of navigating and administering the prescription journey on the patient's behalf. In that simpler era, there was little distinction between filling branded and generic medications.
But starting in the late 1990s, payers added several hurdles to accessing branded therapies: tiered copays, complex prior authorizations, step edits, and exclusion lists.
Retail pharmacies were not designed to navigate these new complex requirements as they lacked the technical capabilities, know-how, and eventually economic incentives to fill branded prescriptions.
The result: the start of an access crisis, with patients showing up at the pharmacy counter only to find their therapy wasn’t available or affordable.
Stage 2: Point Solutions Solve Problems…But Create Bigger Ones
In response, the industry added a plethora of point solutions: copay cards, prior authorization solutions, e-vouchers, bridge and PAP programs.
These well-intentioned efforts actually increased complexity because they were limited in scope, siloed, and ultimately needed to be orchestrated by retail pharmacists, who had neither the time nor the resources to play this role. New vendors, more handoffs, fragmented data. Each point solution made sense on its own but the combination was a swamp for pharmacists, patients, and doctors.
Over ten years, first fill rates for newly launched brands fell from 55% to 28%.
It also became increasingly challenging for manufacturers to get a coherent picture of the patient journey. Opacity and lack of control for commercial teams became expected.
Stage 3: Traditional Hubs—Bandaids on a Hemorrhage
Enter the traditional hub. The argument: a coordination layer stitching together point solutions, third-party tools, and outside fulfillment paths to solve fragmentation.
But without actual control of each step, traditional hubs aren’t solving the root problem. Instead, they’re playing air traffic controllers over an ever-growing network of complexity they can’t directly affect.
Ironically, they haven’t reversed the decline in fill rates caused by the fragmentation they were designed to solve. Rather than reducing complexity, they added another intermediary for patients, pharmacists, doctors, and manufacturers to coordinate with.
For the manufacturer, traditional hubs rely on manual workflows and handoffs, have limited visibility into data locked in disconnected third-party systems, and can’t intervene directly when scripts fall through the cracks. The net effect: continued opacity, lack of control, and increased confusion for everyone involved.
The Learnings
It’s a sad story. Continued innovation leads to continued complexity, which accelerates the degradation of patient access. The opposite of the original goal.
It’s also an instructive one. Point solutions and hub coordination have, in practice, added layers of complexity — fragmented data, disconnected legacy systems, uncoordinated operational processes.
The result: not only is it impossible to know what’s happening in the prescription journey, it’s incredibly challenging to effect change and solve problems. What’s worse, the entire industry has come to accept this as “just the way it is.”
The Next Generation
The access problem remains unsolved by point solutions, hubs, or any other effort to coordinate the existing territory. You cannot coordinate your way out of a swamp.
Instead, the system needs to be rebuilt around a few essential facts:
- Patient expectation: Patients will expect seamless experiences buying and receiving their medication.
- Branded fill complexity: Access barriers and administrative requirements will continue to grow. New precision medication will be increasingly complex to deliver, and health systems, doctors, and pharmacies will have neither the time nor the economic incentive to navigate that complexity.
- Data primacy: AI will be capable of orchestrating extremely complex software and robotics-based workflows, but only if the underlying data is cohesively organized and available in real time.
- Pharma needs: Facing continued pricing pressure and low returns, manufacturers will push to ensure every prescription written is filled with sustainable economics. This means pharma companies will rightly demand real-time visibility and control over the prescription journey.
For the past decade, we at BlinkRx have been building a true alternative prescription journey from the ground up.
We made the hard call early that only a complete system rebuild could deliver a seamless patient experience, efficiently handle branded-fill complexity through actual AI, and give pharma the visibility and control it needs to operate successful brands.
We integrated every aspect of the prescription journey—from patient intake, coverage management, prior authorization support, and financial assistance to fulfillment through a broad pharmacy network—into one, vertically integrated platform with a unified data layer that enables intelligent automation at every step. We call it a Prescription Journey Management Platform.
Innovation often inadvertently creates bigger problems than it solves. Bandaids don’t heal wounds. In deeply entrenched environments, fundamental innovation is hard, and entire industries can remain bogged down for years. In this case, the victim has been patients—increasingly unable to access the medications they’ve been prescribed. It’s imperative to change this and deliver impactful innovation in patient access.
Learn more about BlinkRx here.
Sponsored guest posts are bylined articles that are screened by Drug Channels to ensure a topical relevance to our exclusive audience. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish a guest post on Drug Channels, please contact Marie Caldwell (mcaldwell@hmpglobal.com).
No comments:
Post a Comment